Zerion Pharma A/S

Zerion Pharma A/S
About Us
Quotes
Change country

Follow us:
Share:
Subscribe:

About Us

ZERION has pioneered the Dispersome® technology that greatly enhances the solubility of poorly soluble, oral drugs and improves bioavailability and the therapeutic options for patients. The Dispersome® technology is based on preparing stable amorphous formulations by mixing high loads of the drug compound with beta-lactoglobulin. ZERION develops proprietary drug formulations and offers the Dispersome® technology to established pharma companies as a means to solve their most challenging drug solubility problems. The Dispersome® technology is patent protected and offers in connection with any pharmaceutical drug many additional years of IP protection. ZERION was established in 2019 as a spinout from the University of Copenhagen based on almost a decade of research. (Dispersome® is a trademark of Zerion Pharma A/S)

Quotes

I'm excited to join ZERION in this important role. I believe the company’s technology holds immense potential, and I'm eager to contribute to the company's growth and innovation.

Carl-Åke Carlsson

We are extremely happy to collaborate with both Bayer and Novartis. It is a great opportunity for ZERION to apply our Dispersome® technology to their drug compounds and we are proud to see that our collaborations resulted in valuable insights and learnings for the further development of the technology. It goes without saying that we are thankful to both Bayer and Novartis for their openness to share these findings with the scientific community. Especially for new technologies such as the Dispersome® technology, it is of utmost importance to publish such findings, which ultimately will help to generate more confidence in the technology.

Korbinian Löbmann, CSO of ZERION.

We believe that ZERION’s technology can offer such benefits and have been very pleased with the results, we have seen thus far. We are happy to announce this collaboration that highlights the capabilities of ZERION in the field of drug formulation and the great team that makes it possible.

Alejandro Delgado, Insud Pharma

Hovione is thrilled to be Zerion´s exclusive partner for the application of Dispersome® to the fields of nutraceuticals and diet supplements. The Dispersome® platform and its enabling ingredient – betalactoglobulin or BLG – afford formulators new options which address unmet needs of the industry.

Jean-Luc Herbeaux, CEO of Hovione

The completion of this supply agreement with Arla Foods Ingredients confirms our excellent collaboration that started in 2018 when we identified BLG as a very promising candidate for use in our Dispersome® technology.

Ole Wiborg

We are extremely pleased to have entered into this partnership with ZERION whom we recognize as a very innovative company in the field of oral drug formulations. ZERION´s proprietary Dispersome® technology builds on a new concept of increasing drug solubility by using natural protein-based excipients. I foresee that this will become a valuable component in HOVIONE’s leading amorphous solid dispersion technology platform.

Jean-Luc Herbeaux, Chief Operating Officer in HOVIONE

These are remarkable results that prove that the drug solubility increase provided by our Dispersome® technology translates into significant improvements in bioavailability. This is not the first time we have demonstrated this critical link, but these results are the most convincing to date and exceeded our expectations

Korbinian Löbmann

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Zerion Pharma’s Dispersome® technology published in two peer-reviewed papers through partnerships with pharmaceutical companies

Thu, Jun 08, 2023 10:30 CET

June 8, 2023 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) today announces the publication of joint experimental work on its Dispersome[®] technology in the International Journal of Pharmaceutics and Pharmaceutical Research, two peer-reviewed papers.The work behind the publications originated from two partnership projects, one with Bayer AG and one with Novartis Pharma AG. The former can be accessed here and showcases the interplay between drug loading and dissolution performance in Dispersome[®] formulations on the drug Nimodipine. The

Zerion Pharma and Insud Pharma announce collaboration to develop Dispersome® formulations of marketed drug products

Mon, Aug 29, 2022 12:00 CET

- The two companies have started collaborating on the first two drug products and expect to expand their portfolio. AUGUST 29, 2022 (COPENHAGEN, Denmark). The Danish pharmaceutical company Zerion Pharma A/S (ZERION) and the Spanish pharmaceutical group Insud Pharma, SL today are announcing their collaboration to develop and commercialize drug products applying ZERION’s solubility enhancing Dispersome® technology. ZERION will develop Dispersome® formulations of marketed drug products while INSUD PHARMA will be responsible for the finished product dosage form, the clinical development as

Zerion Pharma and Hovione extend partnership to cover use of the Dispersome® technology platform in nutraceuticals

Tue, Aug 23, 2022 11:00 CET

AUGUST 23, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (ZERION) and Hovione today announced an extension of their collaboration on ZERION’s Dispersome® technology into the nutraceutical/dietary supplements field. Many dietary supplements suffer from low solubility. This results in poor bioavailability and consequently limits the physiological effect of the supplement. To overcome these limitations, the two companies will collaborate and apply the solubility enhancing Dispersome® technology for the development and commercialization of certain nutraceutical products.The first product

Zerion Pharma and Hovione form strategic partnership to market and commercialise the proprietary Dispersome® technology platform

Tue, Feb 22, 2022 15:00 CET

February 22, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (ZERION), a Danish drug development company, is pleased to announce today to have entered into a strategic partnership with HOVIONE, a leading global specialist integrated development and contract manufacturer to accelerate the commercialization of the Dispersome® technology pioneered by ZERION.Through their partnership, HOVIONE and ZERION are offering pharma and biotech companies worldwide access to an innovative drug delivery platform combined with an unparalleled experience in formulation development, scale up and GMP

New study shows that the amount of active drug in cancer tablets may be reduced by 75% using the Dispersome® technology

Mon, Jan 10, 2022 13:30 CET

Will make it possible to ease patients’ life by reduced tablet burden and lower the environmental impact from toxic drug waste.January 10, 2022 (COPENHAGEN, Denmark). The Danish drug development company, Zerion Pharma A/S (ZERION) has completed a new animal study (in dogs) that clearly demonstrates the potential of its patented Dispersome® technology for reducing the amount of drug in tablet formulations. The Dispersome® technology is a leading drug solubility enhancing technology for tablet formulations, resulting in improved bioavailability. ZERION believes that this technology can be

There are no items matching the current filter

There are no more items matching the current filter

Share